Aleksey G. Kazantsev,Leslie M. Thompson,Ruben Abagyan,Malcolm Casale
申请号：
US14892353
公开号：
US09737525B2
申请日:
2014.06.06
申请国别(地区):
US
年份:
2017
代理人:
摘要：
This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntingtons disease, Parkinsons disease, Alzheimers disease, inflammation, and cancer.
